This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

ModernaTX’s Covid vaccine patent found infringed by Düsseldorf court

( March 11, 2025, 10:13 GMT | Official Statement) -- MLex Summary: The Patent Chamber of the Düsseldorf Regional Court has ruled in favor of ModernaTX, finding the BioNTech and Pfizer infringed the patent after March 8, 2022, according to the ruling published by the court. It ordered the two defendants to provide information and accounting related to their use of the patented technology, and declared them liable for damages. The case involves a patent infringement lawsuit related to mRNA technology used in vaccines for Covid-19 vaccines. Moderna pledged not to enforce various mRNA-related patents while the pandemic was ongoing, and reversed the pledge two years later. The court found that Pfizer and BioNTech infringed the patent after Moderna changed its position. The court also found the patent is likely valid.See the ruling in German attached. The case number is O 62/22....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections